TCGA-CN-4742-01A-02R-1514-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.090639269
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.560
- CHOLESTEROL_HOMEOSTASIS+0.520
- ANGIOGENESIS+0.440
- NOTCH_SIGNALING+0.410
- APICAL_JUNCTION+0.400
- COAGULATION+0.400
- UV_RESPONSE_DN+0.400
- TGF_BETA_SIGNALING+0.390
- HEDGEHOG_SIGNALING+0.380
- INFLAMMATORY_RESPONSE+0.380
Top 10 suppressed
- E2F_TARGETS-0.410
- MYC_TARGETS_V1-0.380
- OXIDATIVE_PHOSPHORYLATION-0.360
- MYC_TARGETS_V2-0.350
- DNA_REPAIR-0.250
- G2M_CHECKPOINT-0.250
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.090
- UNFOLDED_PROTEIN_RESPONSE-0.080
- UV_RESPONSE_UP-0.040
- GLYCOLYSIS-0.020
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CV-5970-01A-11R-1686-07 | — | — | 0.911 |
| 2 | BS_RRAEQZ97 | pilocytic astrocytoma | — | 0.910 |
| 3 | TCGA-DK-A1AF-01A-11R-A13Y-07 | — | — | 0.894 |
| 4 | TCGA-BA-5557-01A-01R-1514-07 | — | — | 0.890 |
| 5 | TCGA-A2-A0EO-01A-11R-A034-07 | — | A | 0.885 |
| 6 | TCGA-64-5815-01A-01R-1628-07 | — | cohortA1 | 0.882 |
| 7 | TCGA-BH-A0BR-01A-21R-A115-07 | — | C | 0.878 |
| 8 | TCGA-44-6777-01A-11R-1858-07 | — | cohortA1 | 0.875 |
| 9 | TCGA-CR-6477-01A-11R-1873-07 | — | — | 0.874 |
| 10 | MNG575 | — | — | 0.869 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.560 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.520 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.440 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.410 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.400 | Inavolisib | — uncovered |
| COAGULATION | 0.400 | Binimetinib | — uncovered |
| UV_RESPONSE_DN | 0.400 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.390 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.380 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.380 | Idelalisib | — uncovered |
| MYOGENESIS | 0.380 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.380 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.370 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.360 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.350 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.340 | Inavolisib | — uncovered |
| COMPLEMENT | 0.330 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.310 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.290 | Inavolisib | — uncovered |